Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods:...

Full description

Bibliographic Details
Main Authors: Ahmad Albshesh, Joshua Taylor, Edoardo V. Savarino, Marie Truyens, Alessandro Armuzzi, Davide G. Ribaldone, Ariella Bar-Gil Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancey, Mohamed Korani, Mariann Rutka, Manuel Barreiro-de Acosta, Viktor Domislovic, Gerard Suris, Carl Eriksson, Catarina Alves, Afroditi Mpitouli, Caroline di Jiang, Katja Tepeš, Marina Coletta, Kalliopi Foteinogiannopoulou, Javier P. Gisbert, Hadar Amir-Barak, Mohamed Attauabi, Jakob Seidelin, Waqqas Afif, Carla Marinelli, Triana Lobaton, Daniela Pugliese, Nitsan Maharshak, Anneline Cremer, Jimmy K. Limdi, Tamás Molnár, Borja Otero-Alvarin, Zeljko Krznaric, Fernando Magro, Konstantinos Karmiris, Tim Raine, David Drobne, Ioannis Koutroubakis, Maria Chaparro, Henit Yanai, Johan Burisch, Uri Kopylov
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Journal of Clinical Medicine
Subjects:
Crohn’s disease
anti-TNF failure
treatment response
treatment failure
ustekinumab
vedolizumab
Online Access:https://www.mdpi.com/2077-0383/10/13/2914

Similar Items

Similar Items